Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Myelofibrosis; Anemia|Anemia|Myelofibrosis|Myelofibrosis Due to and Following Polycythemia Vera|Primary Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis|Myelodysplastic Syndromes
DRUG: DISC-0974
Incidence of treatment-emergent adverse events (Phase 1b only), up to 225 days|Incidence of clinically abnormal vital signs (Phase 1b only), up to 225 days|Incidence of clinically abnormal physical exam (Phase 1b only), up to 225 days|Incidence of clinically abnormal electrocardiograms (Phase 1b only), up to 225 days|Incidence of abnormal laboratory test results (Phase 1b only), up to 225 days|Transfusion-dependent (TD) high cohort: transfusion independence, defined as the absence of packed red blood cell (PRBC) transfusions over any rolling 12-week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL (Phase 2 only), up to 225 days|TD low cohort: transfusion independence, defined as the absence of PRBC transfusions over any rolling 16 week interval during the treatment period with a minimum Hgb of 7 g/dL (Phase 2 only), up to 225 days|Non-transfusion-dependent (nTD) cohort: anemia response, defined as the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 2 only), up to 225 days
Anemia response defined per IWG-MRT criteria (Phase 1b only), up to 225 days|TD high and TD low participants will be evaluated for absence of PRBC transfusions for a consecutive, "rolling" 12 week interval during the treatment period (Phase 1b only), up to 225 days|TD high participants will be evaluated for absence of PRBC transfusions with minimum Hgb of 7 g/dL during a terminal 12 week interval during the treatment period (Phase 1b only), up to 225 days|TD low participants will be evaluated for absence of PRBC transfusions with minimum Hgb of 7 g/dL during any rolling 16-week interval during the treatment period (Phase 1b only), up to 225 days|nTD participants will be evaluated for ≥1.5 g/dL increase from baseline Hgb levels during the treatment period (Phase 1b only), up to 225 days|nTD participants will be evaluated for the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 1b only), up to 225 days|Safety, tolerability, PK, and PD of DISC-0974 following repeated SC doses in participants with myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MPN) without excess blasts (collectively referred to as MDS) and anemia (Phase 1b only), up to 225 days|Proportion of participants achieving a mean Hgb increase ≥1 g/dL or ≥2 g/dL from baseline over any rolling 12-week period in absence of RBC transfusions in each cohort (Phase 1b and 2), up to 225 days|Change from baseline in concentration of iron laboratory parameters (Phase 1b and 2), up to 225 days|Change from baseline in concentration of hematologic laboratory parameters (Phase 1b and 2), up to 225 days|Rate and units of RBC transfusion per participant month during the treatment period for each cohort (Phase 1b and 2), up to 225 days|Transfusion-dependent cohorts will be evaluated for proportion of participants who reduce their transfusion requirement by 50%, compared to baseline, over any rolling 12-week period during treatment (Phase 1b and 2), up to 225 days|nTD participants will be evaluated for longest duration of mean Hgb increase of ≥1.5 g/dL from baseline during the treatment period (Phase 1b and 2), up to 225 days|Mean change in Hgb over 12-week treatment periods will be evaluated for all cohorts (nTD, TD low, TD high) (Phase 1b and 2), up to 225 days|Maximum duration of RBC-transfusion-independent response for TD participants (Phase 1b and 2), up to 225 days|Proportion of participants that require dose escalation in each cohort (Phase 1b and 2), up to 225 days|Proportion of participants that improve Functional Assessment of Cancer Therapy-Anemia (FACT-An) subscale by at least 3 points in each cohort during the treatment period (Phase 1b and 2), up to 225 days|Mean hemoglobin increase of ≥1.5 g/dL over a rolling 12-week interval and an increase in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue of 3 points by the end of study (EOS) for nTD participants (Phase 1b and 2), up to 225 days|TD high cohort will be evaluated for absence of packed red blood cell (PRBC) transfusions a terminal 12 week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL (Phase 1b and 2), up to 225 days|TD low cohort: will be evaluated for the absence of PRBC transfusions a terminal 16 week interval during the treatment period with a minimum Hgb of 7 g/dL (Phase 1b and 2), up to 225 days|Non-transfusion-dependent (nTD) cohort: anemia response, defined as the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 1b and 2), up to 225 days|Incidence of treatment-emergent adverse events (Phase 2 only), up to 225 days|Incidence of clinically abnormal vital signs (Phase 2 only), up to 225 days|Incidence of clinically abnormal physical exam (Phase 2 only), up to 225 days|Incidence of clinically abnormal electrocardiogram (Phase 2 only), up to 225 days|Incidence of abnormal laboratory test results (Phase 2 only), up to 225 days|Safety and tolerability of DISC-0974 following repeated SC doses in participants with MF receiving concomitant momelotinib or pacritinib therapy as assessed by TEAEs, vital signs, physical examinations, ECGs, and blood and urine testing (Phase 2 only), 225 days|Cmax-Maximum drug concentration measured in plasma (Phase 1b and 2), up to 225 days|Tmax-Time of maximum drug concentration (Phase 1b and 2), up to 225 days|AUC-Area under the drug concentration time curve (Phase 1b and 2), up to 225 days|Additional PK analysis using a population PK analysis approach may be considered. (Phase 1b and 2), up to 225 days
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.